SQZ Biotechnologies’ $75 Million Initial Public Offering

Latham & Watkins LLP represented SQZ Biotechnologies Company in the transaction. Goodwin Procter LLP advised the underwriters on the deal.

SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) has announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public offering price of US$16.00 per share. All of the shares of common stock are being offered by SQZ. In addition, SQZ has granted the underwriters a 30-day option to purchase up to an additional 661,764 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. SQZ’s common stock trades on the New York Stock Exchange under the ticker symbol “SQZ.”

SQZ Biotech is a unique cell therapy company, utilizing the proprietary CellSqueeze® platform to develop a new generation of cell therapies. SQZ currently focuses on the development of novel treatments that leverage targeted immune modulation to impact oncology and autoimmune diseases.

Latham & Watkins LLP represented SQZ Biotechnologies Company in the transaction with a capital markets deal team led by partners Peter Handrinos (Picture) and Wesley Holmes, with associates Jennifer Yoon, N. Danny Shulman, and Michael Casagrande. Advice was also provided on benefits and compensation matters by partner Matthew Conway, with associate Kirk Porter; on technology transactions matters by partner Alan Tamarelli, with associate Seth Appiah-Opoku; on FDA regulatory matters by partner Ben Haas and counsel Betty Pang, with associates Chad Jennings, Barrett Tenbarge, and Kiera Murphy; on tax matters by partner Jocelyn Noll, with associate Michael Yu; and on other corporate matters by partner Jenna Cooper, with associate Justin McNamee.

The Goodwin team was led by Mitch Bloom, Seo Salimi, Marishka DeToy, Andrew Whitworth and Patty Shields, and included Julie Tibbets, Elizabeth Mulkey, Nikhil Sethi, Duncan Greenhalgh, Olivia Uitto, Roger Cohen, Allyson Maur, Sarah Bock, Brittany McCants, Janet Andolina and Matt Dunay.

Involved fees earner: Janet Andolina – Goodwin Procter; Mitchell Bloom – Goodwin Procter; Sarah Bock – Goodwin Procter; Roger Cohen – Goodwin Procter; Marishka DeToy – Goodwin Procter; Matthew Dunay – Goodwin Procter; Duncan Greenhalgh – Goodwin Procter; Allyson Maur – Goodwin Procter; Brittany McCants – Goodwin Procter; Elizabeth Mulkey – Goodwin Procter; Seo Salimi – Goodwin Procter; Nikhil Sethi – Goodwin Procter; Patty Shields – Goodwin Procter; Julie Tibbets – Goodwin Procter; Olivia Uitto – Goodwin Procter; Andrew Whitworth – Goodwin Procter; Seth Appiah-Opoku – Latham & Watkins; Michael Casagrande – Latham & Watkins; Matthew Conway – Latham & Watkins; Jenna Cooper – Latham & Watkins; Benneville Haas – Latham & Watkins; Peter Handrinos – Latham & Watkins; Wesley Holmes – Latham & Watkins; Chad Jennings – Latham & Watkins; Justin McNamee – Latham & Watkins; Kiera Murphy – Latham & Watkins; Jocelyn Noll – Latham & Watkins; Betty Pang – Latham & Watkins; Kirk Porter – Latham & Watkins; Danny Shulman – Latham & Watkins; Alan Tamarelli Jr. – Latham & Watkins; Barrett Tenbarge – Latham & Watkins; Jennifer Yoon – Latham & Watkins; Michael Yu – Latham & Watkins;

Law Firms: Goodwin Procter; Latham & Watkins;

Clients: Bank of America; Evercore Partners Ltd; SQZ Biotechnologies; Stifel Financial Corp.;

Print Friendly, PDF & Email

Author: Ambrogio Visconti